Published in TB and Outbreaks Week, October 9th, 2001
The Phase I clinical study is a single-center, randomized, double-blind placebo-controlled study to evaluate the safety of ORI-1001 Gel in 30 human volunteers during seven days of cutaneous application. Dr. Karl Beutner, MD and principal investigator for the Phase I study commented: "We look forward to beginning the clinical evaluation of this novel compound for the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week